title: Effect of oxidative phosphorylation uncoupler FCCP and F1F0-ATPase inhibitor oligomycin on the electromechanical activity of human myocardium.
abstract: OBJECTIVE
  The purpose of the study was to determine the influence of oxidative phosphorylation uncoupler FCCP (carbonyl cyanide p-trifluoromethoxy-phenylhydrazone) and F1F0-ATPase inhibitor oligomycin on the parameters of electromechanical activity in human myocardium.
  
  
  METHODS
  The experiments were performed on isolated human ventricle strips from patients undergoing cardiac corrective open heart surgery. Effect of investigative agents was registered using conventional method of registration of cardiac electromechanical activity.
  
  
  RESULTS
  FCCP (10(-9), 10(-8), 10(-7), 10(-6) mol/L) caused the gradual reduction of contraction force (P). The maximal decrement of P (to 8.3 +/- 3.1% (n=5) vs control), was achieved at 10(-6) mol/L FCCP concentration. The duration of action potential at 50% of repolarization (AP50) was decreased only at 10(-7) and 10(-6) mol/L FCCP concentrations, i.e. to 94.3 +/- 1.9% and 55.5 +/- 3.1% (n=4), respectively, vs control. Oligomycin (2 x 10(-5) mol/L) alone decreased P only to 77.8 +/- 5.1% (n=5) and slightly reduced AP50 to 94.2 +/- 6.2% (n=4) vs control. Application of FCCP on top of oligomycin decreased P at the smaller extent than under the action of FCCP alone: the highest concentration of FCCP (10(-6) mol/L) reduced P to 21.1 +/- 4.5% (n=5) vs effect of oligomycin. The duration of AP50 was also less shortened after application of FCCP in the presence of oligomycin. The highest concentration of FCCP (10(-6) mol/L) reduced AP50 to 73.5 +/- 10.1% (n=4) vs effect of oligomycin.
  
  
  CONCLUSIONS
  In conclusion, our data show that the inhibition of F1F0-ATPase reduces the impairment of electromechanical activity caused by oxidative phosphorylation uncoupler FCCP in human myocardium.
authors.affiliation: Institute of Cardiology, Kaunas University of Medicine, Kaunas, Lithuania. dangzab@yahoo.com
authors.forename: D
authors.initials: D
authors.lastname: Zablockaite
authors.forename: V
authors.initials: V
authors.lastname: Gendviliene
authors.forename: I
authors.initials: I
authors.lastname: Martisiene
authors.forename: J
authors.initials: J
authors.lastname: Jurevicius
mesh_terms: D000200:Action Potentials; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002259:Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone / Q000494:pharmacology*; D004563:Electrochemistry / Q000379:methods; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006352:Heart Ventricles / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D009206:Myocardium / Q000378:metabolism*; D009840:Oligomycins / Q000494:pharmacology*; D010100:Oxygen / Q000378:metabolism*; D010766:Phosphorylation; D006180:Proton-Translocating ATPases / Q000378:metabolism*
chemical_list: D004791:Enzyme Inhibitors; D009840:Oligomycins; D002259:Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; D006180:Proton-Translocating ATPases; D010100:Oxygen